Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
IQVIA is a diagnostics & research business based in the US. IQVIA stocks (IQV.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $248.71 – a decrease of 3.3% over the previous week. IQVIA employs 82,000 staff and has a trailing 12-month revenue of around $14 billion.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
Global Trading
| Latest market close | $201.83 |
|---|---|
| 52-week range | $198.11 - $285.61 |
| 50-day moving average | $224.49 |
| 200-day moving average | $246.35 |
| Wall St. target price | $263.13 |
| PE ratio | 37.6937 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $5.54 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $201.83 from 2022-05-20
| 1 week (2022-05-13) | -3.30% |
|---|---|
| 1 month (2022-04-17) | N/A |
| 3 months (2022-02-18) | -11.58% |
| 6 months (2021-11-19) | -24.74% |
| 1 year (2021-05-21) | -15.54% |
|---|---|
| 2 years (2020-05-21) | 40.94% |
| 3 years (2019-05-21) | 49.98% |
| 5 years (2017-05-19) | 143.02% |
Valuing IQVIA stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IQVIA's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IQVIA's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 38x. In other words, IQVIA shares trade at around 38x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
IQVIA's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2796. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IQVIA's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
IQVIA's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.6 billion.
The EBITDA is a measure of a IQVIA's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $14 billion |
|---|---|
| Operating margin TTM | 11.38% |
| Gross profit TTM | $4.6 billion |
| Return on assets TTM | 4.04% |
| Return on equity TTM | 17.75% |
| Profit margin | 7.69% |
| Book value | $31.27 |
| Market capitalisation | $39.8 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IQVIA.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 26.81
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IQVIA's overall score of 26.81 (as at 01/01/2019) is pretty good – landing it in it in the 37th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like IQVIA is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.17/100
IQVIA's environmental score of 1.17 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.76/100
IQVIA's social score of 14.76 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that IQVIA is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 6.88/100
IQVIA's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that IQVIA is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. IQVIA scored a 1 out of 5 for controversy – the highest score possible, reflecting that IQVIA has managed to keep its nose clean.
We're not expecting IQVIA to pay a dividend over the next 12 months.
Over the last 12 months, IQVIA's shares have ranged in value from as little as $198.11 up to $285.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while IQVIA's is 1.4574. This would suggest that IQVIA's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of online gaming stocks.
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
Everything we know about the ProFrac Holding Corp IPO, plus information on how to buy in.
